Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Vivian G Cheung · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $1 — PROJECT SUMMARY APOE4 is a major genetic risk factor for Alzheimer's Disease, which affects millions worldwide. In the United States, over 60% of Alzheimer's patients carry at least one APOE4 allele. Despite three decades of research, the absence of precision medicine targeting APOE4 remains a criti…
Shane P Crotty · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2024 · $810,280 — Project Summary Preclinical studies and early stage human trials evaluating passively transferred broadly neutralizing antibodies (bnAbs) suggest that a vaccine capable of eliciting bnAbs would provide effective protection from HIV infection. However, the difficulty of inducing bnAbs through vaccina…
Mansun Law · SCRIPPS RESEARCH INSTITUTE, THE · 2024 · $883,119 — Project Summary Hepatitis B virus (HBV) infects over 250 million people worldwide and is a leading cause of liver cirrhosis and cancer in many countries. The unique life cycle of HBV involves the generation of covalently closed circular double stranded DNA (cccDNA) in the nucleus of an infected cell…
Jacob Brenner · UNIVERSITY OF PENNSYLVANIA · 2024 · $694,692 — ABSTRACT / PROJECT SUMMARY Despite 50+ years of dissecting the pathways of acute respiratory distress syndrome (ARDS), there are still no drugs which improve its mortality. From a pharmacology perspective, this lack of clinical trial success falls into 2 major buckets: poor drug delivery to the alv…
PARHAM RAMEZANI-RAD · LA JOLLA INSTITUTE FOR IMMUNOLOGY · 2024 · $892,826 — SUMMARY Conventional vaccine strategies have not induced successful protection to diverse HIV strains. mRNA vaccine platforms enable novel modalities of antigen delivery for innovative vaccine strategies. The use of mRNA technology for HIV vaccines holds promise to conquer major barriers to induce p…
Connie Wu · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $371,606 — PROJECT SUMMARY: RNA therapeutics are experiencing a renaissance with the clinical successes of the COVID-19 messenger RNA (mRNA) vaccines. In parallel, nanomaterials have emerged as highly promising vehicles for RNA delivery. However, despite considerable scientific advances in nanoparticle therape…
Susan L Swain · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2024 · $586,250 — ABSTRACT: How Distinct Age-Associated B Cell Subsets Can Protect the Aged from Influenza. With age, the generation of T follicular helpers from naive CD4 T cells, and of germinal center B cells from follicular B cells, both of which are essential for the generation of high affinity antibody (Ab), be…
Michael J Mitchell · UNIVERSITY OF PENNSYLVANIA · 2024 · $349,375 — PROJECT SUMMARY Pre-eclampsia is an obstetric condition that affects 5–8% of all pregnancies and is a leading cause of maternal mortality worldwide. Pre-eclampsia is characterized by the onset of maternal hypertension after 20 weeks of gestation, stemming from insufficient remodeling of the uterine …
Rachel Adria Katzenellenbogen · INDIANA UNIVERSITY INDIANAPOLIS · 2024 · $68,162 — PROJECT SUMMARY/ABSTRACT High-risk human papillomaviruses (HR HPVs) cause 5% of all cancers. There are preventive vaccines against HPV, but less than 2% of the world's target population has received them. This leaves millions of women and men at risk for HPV-associated cervical, anogenital, and hea…
Clayton C Caswell · VIRGINIA POLYTECHNIC INST AND ST UNIV · 2024 · $195,342 — Project Summary Brucella spp. are bacteria that naturally infect a variety of domesticated and wild animals leading to abortions and sterility, and these bacteria are also capable of causing debilitating human infections, which often result from human exposure to infected animals and animal product…
CARL H. JUNE · UNIVERSITY OF PENNSYLVANIA · 2024 · $3,119,164 — OVERALL PROJECT SUMMARY / ABSTRACT The long-term goals of this renewal P01 are to develop next generation immunotherapy with chimeric antigen receptor (CAR) T cells and to translate this research into new therapies with curative potential for patients with blood cancer. The CAR developed at our cent…
Michael Farkas · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2024 · $346,500 — ABSTRACT Gene therapy to treat inherited retinal dystrophies (IRDs) is finally a clinical reality. Adeno-associated virus (AAV) has led the way as a medium to transport a corrective gene to various affected retinal cell types, as well as for CRISPR/Cas9-mediated genome editing. As a long-term soluti…
Brandi Johnson-Weaver · DUKE UNIVERSITY · 2024 · $200,490 — Project Summary/Abstract: Oral immunotherapy with PALFORZIA® is a recently FDA-approved therapy to treat peanut allergy. This therapy requires daily doses of characterized peanut proteins administered orally to peanut hypersensitive individuals. A major limitation of the PALFORZIA® therapy is the po…
Ursula Buchholz · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $1,306,400 — We previously performed codon-pair deoptimization (CPD) of various open reading frames (ORFs) of RSV. This is done by rearranging codons of RSV open reading frames using computer algorithms and de novo gene synthesis to increase the content of normally underrepresented codon-pairs without changing a…
Bernard Moss · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $1,617,431 — During F7'24 progress has been made in developing improved vaccines for mpox and infections caused by other orthopoxviruses. We have continued our collaboration with the company Moderna using mRNAs expressing four modified mpox virus proteins encapsulated in a lipid particle. During the past year, t…
paolo lusso · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $1,410,429 — The development of an HIV vaccine has been hampered by unprecedented challenges, primarily due to the unique properties of the HIV-1 envelope (Env) trimer, which features an extraordinary assortment of immune-evasion tactics, including antigenic variation, heavy glycosylation of exposed surfaces and…
PETER SCHUCK · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · 2024 · $1,425,266 — In this project we seek to develop experimental methods for the study of macromolecular and particle size-distributions. This includes methods for the study of polymorphic dynamic multi-protein complexes that elude classical structural techniques, as well as methods for high-resolution particle size…
Lesia Dropulic · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $2,658,032 — Evaluation of the investigational vaccines in this project are part of the VRC mission related to biodefense and emerging pathogens. Targets include influenza, Ebola, Nipah, West Nile, malaria, and others. Published results from clinical trials have included: VRC 204: Ebola DNA vaccine study: Cli…
Daniel Cesar Douek · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $2,224,710 — The Genome Analysis Core (TGAC), within the Human Immunology Section, was set up in 2014 to fulfill many of the specialist sequencing needs of the Vaccine Research Center (VRC). Currently, the VRC is designing, producing and testing candidate immunogens aimed at eliciting broadly neutralizing antibo…
Kenneth C Bagley · ORLANCE, INC. · 2024 · $300,000 — PROJECT SUMMARY The currently marketed seasonal influenza vaccines have considerable impact on disease, but their efficacy relies on successfully matching the vaccine strains to future circulating virus strains. These vaccines induce neutralizing antibodies primarily against the head region of hemag…